[1]宋晶,熊杰.康柏西普玻璃体内注射治疗特发性脉络膜新生血管[J].眼科新进展,2020,40(2):169-172.[doi:10.13389/j.cnki.rao.2020.0040]
　SONG Jing,XIONG Jie.Intravitreal injection of Conbercept in treatment of patients with idiopathic choroidal neovascularization[J].Recent Advances in Ophthalmology,2020,40(2):169-172.[doi:10.13389/j.cnki.rao.2020.0040]
点击复制

康柏西普玻璃体内注射治疗特发性脉络膜新生血管/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年2期
页码:
169-172
栏目:
应用研究
出版日期:
2020-02-05

文章信息/Info

Title:
Intravitreal injection of Conbercept in treatment of patients with idiopathic choroidal neovascularization
作者:
宋晶; 熊杰
222000　江苏省连云港市，连云港市第一人民医院眼科
Author(s):
SONG Jing; XIONG Jie
Department of Ophthalmology，the First People’s Hospital of Lianyungang，Lianyungang 222000，Jiangsu Province，China
关键词:
抗血管内皮生长因子; 脉络膜新生血管; 康柏西普; 脉络膜厚度
Keywords:
anti-vascular endothelial growth factor; choroidal neovascularization; Conbercept; choroidal thickness
分类号:
R773.4
DOI:
10.13389/j.cnki.rao.2020.0040
文献标志码:
A
摘要:
目的　探究康柏西普玻璃体内注射治疗特发性脉络膜新生血管（idiopathic choroidal neovascularization，ICNV）的疗效。方法　选择2016年1月至2018年1月我院眼科收治的ICNV患者146例（146眼）纳入研究，所有患者均行玻璃体内注射康柏西普治疗，测量治疗前后最佳矫正视力（BCVA）、眼压、黄斑中心凹脉络膜厚度（subfoveal choroidal thickness，SFCT）及上侧脉络膜厚度（superior choroidal thickness，SCT）、下侧脉络膜厚度（inferior choroidal thickness，ICT）、鼻侧脉络膜厚度（nasal choroidal thickness，NCT）、颞侧脉络膜厚度（temporal choroidal thickness，TCT），观察并评价脉络膜新生血管（CNV）渗漏情况，比较患眼治疗前后BCVA、眼压及各区域脉络膜厚度，以及患眼及对侧眼脉络膜厚度差异。结果　与治疗前比较，患眼治疗后 1 d、1个月时BCVA均显著提高(均为P<0.05）。患眼治疗前后眼压比较差异均无统计学意义（均为P>0.05）。随访12个月时患眼渗漏区面积较治疗前均有下降，CNV渗漏治疗有效率为80.82%。治疗前患眼SFCT、NCT 2.2 mm、TCT 2.2 mm、TCT 3.45 mm均显著高于对侧眼（均为P<0.05）；治疗后12个月患眼各部位脉络膜厚度均较治疗前显著降低，差异均有统计学意义（均为P<0.05）。治疗过程中及治疗后均未见严重不良反应发生。结论　玻璃体内注射康柏西普可改善ICNV患者视力，减少视网膜渗漏症状，降低SFCT，效果较好。
Abstract:
Objective　To investigate the curative effect of intravitreal injection of Conbercept in the treatment of idiopathic choroidal neovascularization (ICNV).Methods　Totally 146 ICNV patients (146 eyes) admitted to our Ophthalmology Department from January 2016 to January 2018 were enrolled in the study.All patients underwent intravitreal injection of Conbercept.The best corrected visual acuity (BCVA),intraocular pressure (IOP),subfoveal choroidal thickness (SFCT),superior choroidal thickness (SCT),inferior choroidal thickness (ICT),nasal choroidal thickness (NCT) and temporal choroidal thickness (TCT) before and after treatment were measured.Leakage condition of choroidal neovascularization (CNV) was observed and evaluated.BCVA,IOP and choroidal thickness in each region,and difference in choroidal thickness between affected eyes and contralateral eyes were compared before and after treatment.The choroidal thickness of the affected eye and contralateral eye were compared.Results　Compared with that before treatment,BCVA of the affected eyes significantly improved at 1 day and 1 month after treatment (both P<0.05).There were no significant differences in IOP of the affected eyes before and after treatment (both P>0.05).The leakage area of the affected eyes decreased after 12 months of follow-up.The response rate of CNV leakage treatment was 80.82%.The SFCT,NCT 2.2 mm,TCT 2.2 mm and TCT 3.45 mm of the affected eyes were significantly higher than those of the contralateral eyes (all P<0.05).Compared with that before treatment,the choroidal thickness in all sites of affected eyes significantly decreased at 12 months after treatment (all P<0.05).There were no serious adverse reactions during or after treatment.Conclusion　Intravitreal injection of Conbercept can improve the visual acuity of ICNV patients,reduce the symptoms of retinal leakage,and reduce SFCT that has a good effect.

参考文献/References:

［1］　占宗议，李梓敬，丁小燕.病理性近视继发脉络膜新生血管诊疗现状与进展［J］.中华眼底病杂志，2016，32(1)：104-107.

ZHAN Z Y，LI Z J，DING X Y.Choroidal neovascularization secondary to pathologic myopia：a recent update on diagnosis and treatment［J］.Chin J Ocul Fundus Dis，2016，32(1)：104-107.
［2］　WANG Q，CHAN S Y，JONAS J B，WEI W B.Optical coherence tomography angiography in idiopathic choroidal neovascularization［J］.Acta Ophthalmol，2016，94(4)：415-417.
［3］　王林妮，李志清.应用OCT血管成像技术随访雷珠单抗治疗特发性脉络膜新生血管一例［J］.中华实验眼科杂志，2016，34(3)：217-218.

WANG L N，LI Z Q.Application of OCT angiography in the treatment of idiopathic choroidal neovascularization with ranibizumab in one case［J］.Chin J Exp Surg，2016，34(3)：217-218.
［4］　靖鹏举，李海威，崔静，朱冬梅.抗VEGF药物治疗特发性CNV的效果及对眼压、BCVA、mfERG的影响［J］.国际眼科杂志，2018，18(2)：353-355.

JING P J，LI H W，CUI J，ZHU D M.Analysis on the effect of anti-VEGF drugs on IOP，BCVA and mfERG changes in patients with idiopathic CNV［J］.Int Eye Sci，2018，18(2)：353-355.
［5］　程子芳，王海燕，王雨生.抗血管内皮生长因子药物治疗新生血管性老年性黄斑变性应答不良及无应答现象机制研究的进展［J］.中华眼底病杂志，2017，33(2)：199-202.

CHENG Z F，WANG H Y，WANG Y S.Progress in the study of anti-vascular endothelial growth factor application for the treatment of neovascular age-related macular degeneration and the mechanism of poor and non-response［J］.Chin J Ocul Fundus Dis，2017，33(2)：199-202.
［6］　LIU B，LI B，ZHANG J.Optical coherence tomography angiography of pathological myopia sourced and idiopathic choroidal neovascularization with follow-up［J］.Medicine，2016，95(14)：e3264.
［7］　朱磊，田晓燕，刘涛.玻璃体内注射康柏西普治疗湿性年龄相关性黄斑变性的临床观察［J］.眼科新进展，2017，37(5)：473-476.

ZHU L，TIAN X Y，LIU T.Intravitreal injection of conbercept for wet age-related macular degeneration［J］.Rec Adv Ophthalmol，2017，37(5)：473-476.
［8］　YIN H，FANG X，MA J，CHEN M，YANG Y，GUO S.Idiopathic choroidal neovascularization：intraocular Inflammatory cytokines and the effect of intravitreal ranibizumab treatment［J］.Sci Rep，2016，6(1)：31880.
［9］　HWANG D E，RYOU J H，OH J R，HAN J W，PARK T K，KIM H S.Anti-human VEGF repebody effectively suppresses choroidal neovascularization and vascular leakage［J］.PLoS One，2016，11(3)：e0152522.
［10］　PENG Y，ZHANG X，MI L，LIU B，ZUO C，LI M，et al.Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy［J］.BMC Ophthalmol，2017，17(1)：87.
［11］　PADRN-PREZ N，ARIAS L，RUBIO M，LORENZO D，GARCA-BRU P，CATAL-MORA J，et al.Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovasculopathy［J］.Invest Ophthalmol Vis Sci，2018，59(2)：111-117.
［12］　CHENG Y，SHI X，QU J F，ZHAO M W，LI X X.Comparison of the 1-year outcomes of conbercept therapy between two different angiographic subtypes of polypoidal choroidal vasculopathy［J］.Chin Med J (Engl)，2016，129(21)：2610-2616.
［13］　KIERNAN D F，MIELER W F.Intraocular corticosteroids for posterior segment disease：2012 update［J］.Expert Opin Pharmacother，2012，13(12)：1679-1694.

相似文献/References:

[1]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[2]许瑶 曾骏文.近视眼药物治疗研究进展[J].眼科新进展,2013,33(7):000.
[3]许琴 黄亮 林素香 郑水华 肖煜晨 王雅丽.激光诱导小鼠脉络膜新生血管中膜攻击物与血管生长因子的表达[J].眼科新进展,2013,33(8):000.
[4]詹文捷 梁丽娜 唐由之.骨髓来源细胞参与脉络膜新生血管形成的研究进展[J].眼科新进展,2012,32(1):000.
[5]陈丽娟 苗林.重组人血管内皮抑素对脉络膜新生血管的抑制作用[J].眼科新进展,2012,32(10):000.
[6]金昱 石安娜 刘维锋 石浔 王永波.频域OCT在光动力疗法治疗病理性近视脉络膜新生血管中的应用[J].眼科新进展,2012,32(10):000.
[7]黄志坚 宋艳萍 金中秋 丁琴 陈中山.光动力疗法联合玻璃体内注射Bevacizumab治疗病理性近视合并脉络膜新生血管[J].眼科新进展,2013,33(4):000.
[8]常远 王雨生 曹丰 张健 蔡岩 李鹤一 侯慧媛.在体生物发光成像术观察骨髓来源细胞参与脉络膜新生血管的形成[J].眼科新进展,2013,33(5):000.
[9]雷润佳 胡丹 张鹏 孙丽娟 白倩 闵捷.缺氧对人视网膜色素上皮细胞促血管生成素-1和促血管生成素-2表达的影响[J].眼科新进展,2013,33(5):000.
[10]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[11]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[12]叶蓉,张秋阳,张荟颖,等.不同类型脉络膜新生血管患者对抗VEGF药物治疗应答的差异性[J].眼科新进展,2022,42(12):952.[doi:10.13389/j.cnki.rao.2022.0195]
　YE Rong,ZHANG Qiuyang,ZHANG Huiying,et al.Differences in responses to anti-vascular endothelial growth factor drugs of patients with different types of choroidal neovascularization[J].Recent Advances in Ophthalmology,2022,42(2):952.[doi:10.13389/j.cnki.rao.2022.0195]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2020-02-05